Efficacy and Safety of 4-Weekly Docetaxel for Castration-Resistant Prostate Cancer.
Yamashita T, Shiota M, Machidori A, Kobayashi S, Matsumoto T, Monji K, Kashiwagi E, Takeuchi A, Takahashi R, Inokuchi J, Shiga KI, Yokomizo A, Eto M.
Yamashita T, et al. Among authors: monji k.
Cancer Invest. 2021 Mar;39(3):251-256. doi: 10.1080/07357907.2020.1871486. Epub 2021 Jan 14.
Cancer Invest. 2021.
PMID: 33393849
Clinical Trial.